Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Anti-Influenza Hyperimmune IVIG in Healthy Subjects
NCT02037282Phase 1Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2014
- Primary completion
- Dec 2014
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 1, open-label, single-arm trial of immune globulin in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Hemagglutination Inhibition Titer at Day 28. Planned start Jan 2014; status: withdrawn.
02
Drugs
immune globulin
03
Conditions
influenza
Beyond the preview
Go deeper on NCT02037282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02037282.